Please ensure Javascript is enabled for purposes of website accessibility

UMB, MedImmune agree to collaborate (access required)

The University of Maryland, Baltimore and MedImmune Inc., of Gaithersburg, a subsidiary of British drug maker AstraZeneca PLC, announced they have entered into a five-year, $6 million agreement to work on novel bioscience research in Maryland.